Moderna (MRNA) to Release Earnings on Thursday

Moderna (NASDAQ:MRNA) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Moderna to post earnings of ($2.90) per share and revenue of $130.35 million for the quarter.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $26.52 on Thursday. Moderna has a 52 week low of $23.15 and a 52 week high of $170.47. The stock has a market capitalization of $10.25 billion, a P/E ratio of -2.86 and a beta of 2.23. The stock’s fifty day moving average is $30.48 and its 200 day moving average is $39.07.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MRNA. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. JPMorgan Chase & Co. dropped their price objective on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. UBS Group decreased their target price on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Finally, The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and reduced their price target for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.